A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
Shamsi, Kohkan
A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. [electronic resource] - Investigative radiology Nov 2006 - 822-30 p. digital
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
0020-9996
10.1097/01.rli.0000242836.25299.8f doi
Aged
Blood Chemical Analysis
Dose-Response Relationship, Drug
Gadolinium--administration & dosage
Humans
Injections
Magnetic Resonance Angiography
Middle Aged
Organometallic Compounds--administration & dosage
Peripheral Vascular Diseases--blood
Urinalysis
A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. [electronic resource] - Investigative radiology Nov 2006 - 822-30 p. digital
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
0020-9996
10.1097/01.rli.0000242836.25299.8f doi
Aged
Blood Chemical Analysis
Dose-Response Relationship, Drug
Gadolinium--administration & dosage
Humans
Injections
Magnetic Resonance Angiography
Middle Aged
Organometallic Compounds--administration & dosage
Peripheral Vascular Diseases--blood
Urinalysis